Cancer Programs Critical For 'New AstraZeneca' As Price Pressure, Regulatory Changes Loom In 2017
Executive Summary
CEO discussed oncology programs crucial to AstraZeneca’s future and was upbeat on US pricing pressure and Brexit as he insisted the company was "rapidly approaching a return to growth."
You may also be interested in...
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.
Pharma Earnings Calls Reveal US/EU Trump Divide
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.
AstraZeneca Works To Replicate China Success In Russia
AstraZeneca sees similarities with China in the Russian market and is hoping to replicate its success there, says global product and portfolio strategy head Mark Mallon.